Aplagon Overview

  • Founded
  • 2009
  • Status
  • Private
  • Employees
  • 2
  • Latest Deal Type
  • Crowdfunding
  • Latest Deal Amount
  • $2.62M
Latest Deal Amount
  • Investors
  • 6

Aplagon General Information


Developer of antithrombotic compounds designed to treat complications of vascular intervention-related blood vessel occlusions. The company's compounds are engaged in developing biological mimetics of heparin proteoglycan, for the clinical management of vascular injury-related thrombotic occlusions and ischemic reperfusion injuries, enabling patients to get unique and effective antithrombotic medicines with important safety advantages.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Primary Office
  • Biomedicum Helsinki 2A
  • Tukholmankatu 8 A
  • 00290 Helsinki
  • Finland
+358 040 0000000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Aplagon Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Equity Crowdfunding 28-Apr-2021 $2.62M 00000 000.00 Completed Clinical Trials - Phase 1
4. Later Stage VC 26-Jul-2016 00000 Completed Generating Revenue
3. Later Stage VC 09-Jun-2015 00000 00000 00.000 Completed Generating Revenue
2. Early Stage VC 11-Apr-2013 $59.4K Completed Generating Revenue
1. Early Stage VC 01-Apr-2011 $59.4K $59.4K 00000 Completed Generating Revenue
To view Aplagon’s complete valuation and funding history, request access »

Aplagon Cap Table

Stock # of Shares
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Ordinary 00,000 000.00 000.00 00 000.00 00.000
Ordinary 00,000 00.00 00.00 00 00.00 00.000
To view Aplagon’s complete cap table history, request access »

Aplagon Executive Team (6)

Name Title Board Seat Contact Info
Aki Prihti Chief Executive Officer
Riitta Lassila Ph.D Co-Founder & Chief Scientific Officer
Sakari Lassila Co-Founder & Chairman
Kai Lindevall Ph.D Co-Founder & Board Member
Steven Myint Ph.D Board Member & Chairman of the Scientific Advisory Board
You’re viewing 5 of 6 executive team members. Get the full list »

Aplagon Board Members (8)

Name Representing Role Since
Harry Holthöfer Aplagon Board Member 000 0000
Jim Phillips Aplagon Board Member 000 0000
Kai Lindevall Ph.D Aplagon Co-Founder & Board Member 000 0000
Sakari Lassila Aplagon Co-Founder & Chairman 000 0000
Steven Myint Ph.D Aplagon Board Member & Chairman of the Scientific Advisory Board 000 0000
You’re viewing 5 of 8 board members. Get the full list »

Aplagon Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Aplagon Investors (6)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Gösta Serlachius Fine Arts Foundation Corporation Minority 000 0000 000000 0
Jenny and Antti Wihuri Foundation Limited Partner Minority 000 0000 000000 0
Innovestor Venture Capital Minority 000 0000 000000 0
University of Helsinki Endowment Limited Partner Minority 000 0000 000000 0
Finnvera Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 6 investors. Get the full list »